Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized blinded study of SYN023 vs human rabies immune globulin for post-exposure prophylaxis of rabies in adults
TCTR20190507001Phase 3Not yet recruiting
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zamerovimab + mazorelvimab in rabies (2 arms), sponsored by Xingmeng Biopharmaceutical. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on TCTR20190507001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190507001.